Tyler’s Law

HR2004 was introduced on March 10, 2025, and referred to the House Committee on Energy and Commerce, where it has remained for over 13 months with zero subsequent actions. The bill directs the Secretary of HHS to conduct a study on fentanyl testing frequency, costs, benefits, and patient impacts in emergency departments, and then issue guidance. Critically, the bill authorizes no funding for the study or any testing programs, and imposes no mandates on hospitals or testing companies. There is no mandatory timeline enforcement mechanism.

Because the bill is purely a study-and-guidance directive with zero authorized appropriations and no regulatory force, there is no direct revenue mechanism for any publicly traded company. Diagnostic testing companies like Quest Diagnostics ($DGX) and Laboratory Corporation of America ($LH) would only be affected if this study led to future mandated testing with reimbursement—a multi-year, multi-step legislative path that has not begun. Current legislation does not change their addressable market.

Looking at $DGX real market data, the stock closed at $194.67 on April 30, 2026, down 0.82% over 7 days and 0.67% over 30 days. Recent trading shows volatility from a high of $205.04 on April 21 to a low of $189.32 on April 29. These moves are driven by broader market factors and company fundamentals, not by HR2004, which has had no price-impacting events since its introduction.

Legislative path forward: the bill requires committee markup, House floor passage, Senate introduction and passage, and presidential action. With 54 cosponsors but no Senate companion bill and no committee activity in over a year, the probability of enactment during the 119th Congress is extremely low.